HealthInvest Partners AB recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
BIBLIOTEKSGATAN 29 STOCKHOLM, V7 SE-114 35
As of the latest 13F report, the guru’s equity portfolio contained 53 stocks valued at a total of $52.00Mil. The top holdings were UTMD(18.25%), CAH(14.84%), and CI(10.24%).
According to GuruFocus data, these were HealthInvest Partners AB’s top five trades of the quarter.
GSK PLC
The guru established a new position worth 150,000 shares in NYSE:GSK, giving the stock a 10.18% weight in the equity portfolio. Shares traded for an average price of $33.31 during the quarter.
On 02/18/2023, GSK PLC traded for a price of $35.88 per share and a market cap of $73.46Bil. The stock has returned -15.25% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, GSK PLC has a price-earnings ratio of 4.33, a price-book ratio of 5.73, a price-earnings-to-growth (PEG) ratio of 1.99, a EV-to-Ebitda ratio of 7.58 and a price-sales ratio of 1.89.
The price-to-GF Value ratio is 1.08, earning the stock a GF Value rank of 5.
CVS Health Corp
The guru established a new position worth 52,000 shares in NYSE:CVS, giving the stock a 9.359999999999999% weight in the equity portfolio. Shares traded for an average price of $96.48999999999999 during the quarter.
On 02/18/2023, CVS Health Corp traded for a price of $88.58 per share and a market cap of $113.75Bil. The stock has returned -11.34% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CVS Health Corp has a price-earnings ratio of 28.39, a price-book ratio of 1.62, a price-earnings-to-growth (PEG) ratio of 9.46, a EV-to-Ebitda ratio of 13.81 and a price-sales ratio of 0.36.
The price-to-GF Value ratio is 0.91, earning the stock a GF Value rank of 6.
McKesson Corp
The guru sold out of their 13,000-share investment in NYSE:MCK. Previously, the stock had a 9.33% weight in the equity portfolio. Shares traded for an average price of $372.97 during the quarter.
On 02/18/2023, McKesson Corp traded for a price of $366.86 per share and a market cap of $50.24Bil. The stock has returned 34.71% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, McKesson Corp has a price-earnings ratio of 16.82, a EV-to-Ebitda ratio of 10.69 and a price-sales ratio of 0.19.
The price-to-GF Value ratio is 1.41, earning the stock a GF Value rank of 1.
Gilead Sciences Inc
HealthInvest Partners AB reduced their investment in NAS:GILD by 44,240 shares. The trade had a 5.76% impact on the equity portfolio. During the quarter, the stock traded for an average price of $79.19.
On 02/18/2023, Gilead Sciences Inc traded for a price of $84.76000000000001 per share and a market cap of $105.70Bil. The stock has returned 43.06% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Gilead Sciences Inc has a price-earnings ratio of 23.22, a price-book ratio of 5.01, a EV-to-Ebitda ratio of 14.84 and a price-sales ratio of 3.90.
The price-to-GF Value ratio is 1.17, earning the stock a GF Value rank of 3.
KemPharm Inc
HealthInvest Partners AB reduced their investment in NAS:KMPH by 420,000 shares. The trade had a 5.54% impact on the equity portfolio. During the quarter, the stock traded for an average price of $5.08.
On 02/18/2023, KemPharm Inc traded for a price of $5.5 per share and a market cap of $189.78Mil. The stock has returned -2.48% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, KemPharm Inc has a price-book ratio of 2.02, a EV-to-Ebitda ratio of -3.50 and a price-sales ratio of 17.30.
The price-to-GF Value ratio is 4.78, earning the stock a GF Value rank of 1.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
